DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo

CEL-SCI Corp (NYSEMKT: CVM)

1.04 0.15 (16.21%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CVM $1.04 16.21%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.93
Previous Close $0.89
Daily Range $0.90 - $1.04
52-Week Range $0.54 - $1.32
Market Cap $95.2M
P/E Ratio -1.99
Dividend (Yield) $0.00 (0.0%)
Volume 1,798,348
Average Daily Volume 440,872
Current FY EPS -$0.39

Sector

Healthcare

Industry

Drug Makers

CEL-SCI Corp (CVM) Description

The Company engages in the research and development of drugs and vaccines. Its most advanced product, Multikine, manufactured using the Company's proprietary cell culture technologies, is being developed for the treatment of cancer. Website: http://www.cel-sci.com/

News & Commentary Rss Feed

One Biotech Stock to Avoid

Our investing community's latest pick to avoid: Vical.

CEL-SCI Reports Third Consecutive Month of Record Patient Enrollment in '15 for Phase III Head, Neck

CEL-SCI Reports Third Consecutive Month of Record Patient Enrollment in '15 for Phase III Head, Neck Cancer Trial

Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity

CEL-SCI Corp (CVM) Falls: Stock Goes Down 7% - Tale of the Tape

CEL-SCI Corporation (CVM) in Focus: Stock Jumps 5.6% - Tale of the Tape

CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head an

CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial

Cel-Sci Is Closer To The Finish Line, But Skip This Stock For Now

Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop

CEL-SCI Corp. (CVM) in Focus: Stock Adds 7.5% in Session - Tale of the Tape

CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romani

CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romania

CEL-SCI Quarterly Patient Enrollment In Its Head And Neck Cancer Phase III Trial Increases Eight Fol

CEL-SCI Quarterly Patient Enrollment In Its Head And Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period

See More CVM News...

CVM's Top Competitors

CVM $1.04 (16.21%)
Current stock: CVM
AMGN $167.91 (-0.74%)
Current stock: AMGN
BIIB $401.71 (-6.64%)
Current stock: BIIB
CELG $118.71 (2.26%)
Current stock: CELG